Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-241 first-in-human study in EGFR-mutant advanced NSCLC after EGFR TKI resistance
NL-OMON59976Phase 2Recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PFL-241 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pierre Fabre Laboratories. Started Sep 2024; status: recruiting.
02
Drugs
PFL-241
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59976.